Intra-Cellular Therapies (ITCI): CNS Summit Data Supports KOL Observations, Reit Overweight - PiperJaffray
- Wall Street dips on Trump protectionism, Qualcomm drag
- Yahoo! (YHOO) Tops Q4 EPS by 4c; Sees Verizon Deal Closing in Q2, Not Q1
- Aetna's (AET) Humana (HUM) Takeover Blocked by Judge as Anticompetative
- Trump signs order withdrawing U.S. from Trans-Pacific trade deal
- After-Hours Stock Movers 1/23: (REXX) (MRCY) (SYNC) Higher; (FSM) (OCUL) (CASC) Lower (more...)
Get the Pulse of the Market with StreetInsider.com's Pulse Picks. Get your Free Trial here.
Piper Jaffray analyst, Charles Duncan, reiterated his Overweight rating on shares of Intra-Cellular Therapies (NASDAQ: ITCI) after the company announced oral and poster presentations of its ITI-007 (Lumateperone) program in schizophrenia at the recent CNS Summit.
The presentations outlined potential confounders of the infamous 302 trial, including a high placebo response; however, the broader focus was on the programmatic totality of efficacy, differentiating safety, and tolerability of ‘007 across these late-stage trials. Based on these results, two well controlled and positive US trials, positive feedback at CNS Summit and the analyst's recent KOL call, he continues to believe that Intra-Cellular may have a data package in schizophrenia which could support NDA submission.
The development and regulatory path forward continues to be a point of debate but the analyst suggests buying in advance of a possible FDA meeting and guidance for ‘007 (possibly in the next 3 months).
No change to the price target of $22.
Shares of Intra-Cellular Therapies closed at $12.40 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Halozyme Therapeutics (HALO): Top Pick Under A Trump Presidency - Piper Jaffray
- UPDATE: Wells Fargo Downgrades Verizon Communications (VZ) to Market Perform
- Procter & Gamble (PG) PT Raised to $96 at UBS Following 2Q Report
Create E-mail Alert Related CategoriesAnalyst Comments
Related EntitiesPiper Jaffray, The Children's Investment Fund (TCI), Charles Duncan
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!